 | Up a level |
Zimmer, Kai; Kocher, Florian; Untergasser, Gerold; Kircher, Brigitte; Amann, Arno; Baca, Yasmine; Xiu, Joanne; Korn, W Micheal; Berger, Martin D; Lenz, Heinz-Josef; Puccini, Alberto; Fontana, Elisa; Shields, Anthony F; Marshall, John L; Hall, Michael; El-Deiry, Wafik S; Hsiehchen, David; Macarulla, Teresa; Tabernero, Josep; Pichler, Renate; ... (2023). PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system. NPJ precision oncology, 7(1), p. 64. Springer Nature 10.1038/s41698-023-00409-5
Kim, Richard D; Sarker, Debashis; Meyer, Tim; Yau, Thomas; Macarulla, Teresa; Park, Joong-Won; Choo, Su Pin; Hollebecque, Antoine; Sung, Max W; Lim, Ho-Yeong; Mazzaferro, Vincenzo; Trojan, Joerg; Zhu, Andrew X; Yoon, Jung-Hwan; Sharma, Sunil; Lin, Zhong-Zhe; Chan, Stephen L; Faivre, Sandrine; Feun, Lynn G; Yen, Chia-Jui; ... (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer discovery, 9(12), pp. 1696-1707. American Association for Cancer Research 10.1158/2159-8290.CD-19-0555
